secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-138931
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal Q1 cash burn $84.1M; resmetirom NDA on track for Q2 2023 with Breakthrough Therapy
--------------------------------------------------------------------------------

- Cash and securities $329.5M at March 31, 2023, down from $358.8M at Dec 31, 2022.
- Operating expenses $78.3M for Q1 2023, up from $57.6M in Q1 2022; R&D $62.2M, G&A $16.2M.
- Resmetirom NDA for NASH with fibrosis remains on track for Q2 2023; FDA Breakthrough Therapy designation received.
- MAESTRO-NASH trial enrollment complete; primary results to be presented at EASL in June 2023.
- Interest income rose to $3.8M from $0.1M; interest expense $2.3M from loan facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/0001193125-23-138931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312523138931/d398921d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer